Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: Stock Traders Daily
Provider: S&P Capital IQ – STARS Reports
Provider: ValuEngine, Inc.

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Valeant Pharmaceuticals International responds to Allergan 's rejection of merger proposal

Tuesday, 13 May 2014 08:01am EDT 

Valeant Pharmaceuticals International Inc:Says that it has responded to Allergan Inc.'s rejection of Valeant's proposal to combine with Allergan for $48.30 in cash and 0.83 shares of Valeant common stock for each Allergan share.Receives Allergan's letter rejecting Valeant's offer on May 12. 

Company Quote

-3.35 -1.80%
4:00pm EDT